ArticleJournal of virology2026
Cyclosporine A rescues the influenza virus fusion with IFITM3-expressing cells by relocating the restriction factor to intraluminal vesicles of multivesicular bodies.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Interferon-induced transmembrane protein 3 (IFITM3) blocks fusion of many enveloped viruses with endosomes, likely by rigidifying the cell membrane. We and others have previously reported that cyclosporine A (CsA) treatment rescues the ability of the influenza A virus (IAV) to fuse with and infect IFITM3-expressing cells, but the mechanism of such rescue remained controversial. Here, we employed correlative light-electron microscopy (CLEM) and on-section electron tomography workflow to visualize the IAV fusion intermediates arrested by IFITM3. Most common intermediates were tight IAV contacts with the limiting membrane and intraluminal vesicles of late endosomes. A hemifusion intermediate was also detected. We further visualized the effect of CsA on IFITM3 localization by immunoelectron microscopy (immuno-EM), which revealed a marked relocation of IFITM3 from the limiting membrane to intraluminal vesicles of endosomes. This CsA-induced IFITM3 sequestration in intraluminal vesicles likely relieves the block for IAV fusion with the limiting membrane of endosomes that culminates in a release of the viral nucleoprotein complex into the cytoplasm.IMPORTANCEThe mechanism by which interferon-induced transmembrane protein 3 (IFITM3) inhibits the fusion of diverse enveloped viruses with endosomes is not fully understood. Using correlative light-electron microscopy (CLEM) and on-section electron tomography, we detected IFITM3-arrested influenza A virus fusion intermediates with the limiting membrane and intraluminal vesicles of late endosomes. The most common arrested intermediate was a tight contact between the viral membrane and the limiting membrane of late endosomes, which formed more frequently compared to tight contacts with intraluminal vesicles. Immunoelectron microscopy (immuno-EM) revealed that pretreatment of IFITM3-expressing cells with cyclosporine A induced relocation of IFITM3 from the limiting membrane to intraluminal vesicles of endosomes and rescued the influenza A virus fusion. Collectively, these findings imply that the influenza virus fuses with the limiting membrane of endosomes, but not with intraluminal vesicles, leading to productive infection, and that IFITM3 enrichment at these sites is critical for blocking viral fusion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.